.png){kind=icon}
.png){kind=icon}
Return
GLP-1 receptor agonists in type 1 diabetes: a new frontier for cardiovascular prevention?
.png){kind=icon}
PRE
AI
Q
B
Y
Y
J
C
DOI：10.1093/eurjpc/zwag371.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Type 1 diabetes has traditionally been viewed through the lens of absolute insulin deficiency. This framing remains clinically essential, but it is increasingly incomplete. With longer survival, rising obesity, and greater cumulative exposure to glycaemic and non-glycaemic risk factors, type 1 diabetes has become a lifelong cardiometabolic condition. Cardiovascular disease and kidney disease remain major determinants of prognosis, even in the era of continuous glucose monitoring, insulin pumps, and automated insulin delivery.1 The central question is therefore no longer only how to improve glycaemic control, but how to prevent pre-mature cardiorenal disease across decades of living with type 1 diabetes.
Journal
IF:
7.5
Papers:
5.8K
Citations:
1.2W
View more organizations